IN DEVELOPMENT: CB003
Cubed's first compound in development: a stacked multiple-API formula "Ayahuasca Pill"
DMT
Derived from plants
Harmine MAO-I | 5 mg
A harmala alkaloid from the B. Caapi vine
We will partner with universities to conduct clinical trials then produce our proprietary drug compounds and manufacture for our partners.
TACKLING THE MENTAL HEALTH CRISIS
A Vast Global Potential Market already used for centuries for:
DEPRESSION – ADDICTION - POST-TRAUMATIC STRESS DISORDER (PTSD)Growing psychedelic research & acceptance for treating depression FDA is fast-tracking Psilocybin as a ”Breakthrough Treatment” COVID-19 has increased global mental health awareness
ACTIVE GOVERNMENTAL RESPONSERising Health care costs force governments to look for economic therapiesCannabis legalization opened new regulations, infrastructure & reduces stigmaGovernments leading the charge: U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) invested $27 million in psychedelicsSource: https://thedalesreport.com/psychedelics/what-the-u-s-militarys-27-million-investment-in-novel-psychedelic-type-drugs-could-mean-for-veterans
© 2021 Cubed Biotech Inc | All rights Reserved
© 2021 Cubed Biotech Inc | All rights Reserved